Clinical trials: Still Disease, Juvenile Onset
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic…
- Trial name
- anaSTILLs (NCT03265132)
- Testing
- anakinra
- Where
- 39 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.
This study aims to evaluate safety information in patients with HLH/MAS in Still's disease exposed to Gamifant.
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
- Trial name
- NCT07909005
- Testing
- Local laboratory testing, Local Lab Tests
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- Swedish Orphan Biovitrum
Systemic Juvenile Idiopathic Arthritis (sJIA), Adult Onset Still's Disease (AOSD)
An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks…
- Trial name
- NCT07706868
- Testing
- Anakinra (Kineret®)
- Sponsor
- Swedish Orphan Biovitrum
Still Disease
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease
- Trial name
- NCT07625384
- Testing
- Goflikicept, Olokizumab
- Where
- 25 sites in Russia
- Volunteers
- 52 people
- Sponsor
- R-Pharm International, LLC
Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
- Conditions
- Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset, Still's Disease, Adult-Onset
- Trial name
- AMETISTA (NCT06992505)
- Where
- 2 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Swedish Orphan Biovitrum
Still Disease, Juvenile Onset
Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
The purpose of the study is to evaluate and characterize long-term safety of Kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (SJIA).
- Trial name
- NCT03932344
- Testing
- Anakinra
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Swedish Orphan Biovitrum
Still´s Disease
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
- Trial name
- NCT07203001
- Testing
- MAS825
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Macrophage Activation Syndrome, Still's Disease, Adult-Onset
Assessment of Macrophage Activation syndromE in STill's Disease
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
- Conditions
- Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
- Trial name
- AMETHYST (NCT06405152)
- Testing
- Chart review
- Where
- 11 sites in United States, Canada and 5 more
- Volunteers
- 75 people
- Sponsor
- Swedish Orphan Biovitrum
Familial Mediterranean Fever, Still Disease
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including…
- Conditions
- Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
- Trial name
- NCT07517250
- Where
- Switzerland
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Still's Disease, Adult-Onset
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
The objective of this study is to assess safety, tolerability and early signs of efficacy of the investigational drug Tadekinig alfa in Adult-onset Still's disease, a rare polygenic auto-inflammatory disorder for which treatment…
- Trial name
- NCT02398435
- Testing
- Tadekinig alfa (recombinant human IL-18 binding protein)
- Where
- 20 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- AB2 Bio Ltd.
Juvenile Rheumatoid Arthritis
Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis
The primary objective of this study was to determine the efficacy of etanercept in pediatric patients with systemically active system onset juvenile rheumatoid arthritis (SOJRA).
- Trial name
- NCT00078806
- Testing
- Etanercept
- Volunteers
- 19 people
- Sponsor
- Amgen
Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]).
- Trial name
- NCT05814159
- Testing
- Anakinra
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Swedish Orphan Biovitrum
Active Systemic, Onset Juvenile Idiopathic Arthritis
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
This study has the following objectives: Primary objective: To determine the safety and tolerability of oral ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and…
- Trial name
- SOJIA (NCT00570661)
- Testing
- ITF2357
- Where
- 5 sites in Romania, Serbia
- Volunteers
- 17 people
- Sponsor
- Italfarmaco
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum